Currently, clinical treatment mainly relies on oral DPP-4 inhibitors to maintain GLP-1 levels
Apr 25, 2025, 09:30 ET Federal court ruling leaves in place FDA's decision resolving the shortage of Wegovy and Ozempic , which are fully available nationwide, and ends the grace period for pharmacies to make or sell compounded "versions" of these medicines Separate federal court ruling permanently bars MediOak Pharmacy LLC from marketing or selling illegitimate "semaglutide" drugs Legal wins build on 111 lawsuits filed by Novo Nordisk across 32 states against entities unlawfully marketing and selling compounded "semaglutide" drugs, helping safeguard Americans from knockoffs made with unsafe or illicit foreign API Novo Nordisk is dedicated to dialogue with companies to support patient access to authentic, FDA-approved Wegovy under the care of a licensed healthcare professional PLAINSBORO, N.J., April 25, 2025 /PRNewswire/ -- Yesterday, a Texas federal court ruled in favor of Novo Nordisk and FDA, denying a compounding trade association's motion to freeze the FDA's decision to end the shortage of semaglutide injectable medicines
Perhaps most intriguing is the research on doxorubicin-induced cardiotoxicity
Even though the data is extensive it is not enough to explain any relationship between these molecules and the independent MetS factors, or any mechanism by which these molecules could be involved in the pathophysiology
